Jafron Biomedical Co

Jafron Biomedical Co Equity

The The Equity of Jafron Biomedical Co (300529.SZ) as of Oct 20, 2026 is 3.47 B CNY. In the previous year, The Equity was 3.33 B CNY — a change of 4.13% (higher).

Equity

3.47 BCNY

YoY

4.13%

Last updated:

In 2025, Jafron Biomedical Co's equity was 3.47 B CNY, a 4.13% increase from the 3.33 B CNY equity in the previous year.

The Jafron Biomedical Co Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
1.70 B CNY
Jan 1, 2019
2.14 B CNY
Jan 1, 2020
2.81 B CNY
Jan 1, 2021
3.36 B CNY
Jan 1, 2022
3.57 B CNY
Jan 1, 2023
3.15 B CNY
Jan 1, 2024
3.33 B CNY
Jan 1, 2025
3.47 B CNY
The Jafron Biomedical Co Equity history
YEAREquityYoY
3.47 BCNY+4.13%
3.33 BCNY+5.92%
3.15 BCNY-11.94%
3.57 BCNY+6.41%
3.36 BCNY+19.67%
2.81 BCNY+31.01%
2.14 BCNY+26.14%
1.70 BCNY+22.10%
1.39 BCNY+17.49%
1.18 BCNY+109.92%
564.06 MCNY+24.68%
452.42 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Jafron Biomedical Co Stock analysis

What does Jafron Biomedical Co do? Jafron Biomedical Co., Ltd. generates revenue through the research, development, production, and sale of hemoperfusion products and medical equipment. The company offers a range of items including disposable hemoperfusion devices, hemoperfusion machines, disposable bilirubin adsorbers, the DX-10 blood purification machine, suture needles, and resins bandage. These products are utilized for treating conditions such as uremia, poisoning, severe liver diseases, autoimmune diseases, and multisystem organ failure. The primary customers for these medical solutions are hospitals across China, where the company’s products are applied in more than 3000 hospitals within 31 provinces. As a China-based company, Jafron Biomedical Co., Ltd. focuses on the design, manufacture, and distribution of biological materials and medical equipment to support healthcare providers in these regions. The company operates from its headquarters in Zhuhai, Guangdong, and supports its operations with a workforce of 3,003 full-time employees. By engaging in the full lifecycle of its products from research to sale, the firm serves the medical sector with specialized equipment for blood purification and related therapeutic needs. Jafron Biomedical Co is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Jafron Biomedical Co's Equity

Jafron Biomedical Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Jafron Biomedical Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Jafron Biomedical Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Jafron Biomedical Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Jafron Biomedical Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Jafron Biomedical Co stock

The Equity of Jafron Biomedical Co is 3.47 B CNY in 2025.

The Equity of Jafron Biomedical Co changed from 3.33 B CNY to 3.47 B CNY, representing a 4.13% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Jafron Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

The Equity's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Jafron Biomedical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Jafron Biomedical Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Jafron Biomedical Co